Cargando…

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse

OBJECTIVE: To determine the cutoffs that optimized the agreement between (18)F‐Florbetapir positron emission tomography (PET) and Aβ1‐42, Aβ1‐40, tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the LUMIPULSE G600II instrument, we quantified the levels of these four biomarkers in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alcolea, Daniel, Pegueroles, Jordi, Muñoz, Laia, Camacho, Valle, López‐Mora, Diego, Fernández‐León, Alejandro, Le Bastard, Nathalie, Huyck, Els, Nadal, Alicia, Olmedo, Verónica, Sampedro, Frederic, Montal, Victor, Vilaplana, Eduard, Clarimón, Jordi, Blesa, Rafael, Fortea, Juan, Lleó, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764494/ https://www.ncbi.nlm.nih.gov/pubmed/31464088 http://dx.doi.org/10.1002/acn3.50873

Ejemplares similares

Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study
por: Pegueroles, Jordi, et al.
Publicado: (2018)

AMYQ: An index to standardize quantitative amyloid load across PET tracers
por: Pegueroles, Jordi, et al.
Publicado: (2021)

APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls
por: Sampedro, Frederic, et al.
Publicado: (2015)

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease
por: Jimenez, Amanda, et al.
Publicado: (2017)

APP‐derived peptides reflect neurodegeneration in frontotemporal dementia
por: Illán‐Gala, Ignacio, et al.
Publicado: (2019)

Challenges associated with biomarker-based classification systems for Alzheimer's disease
por: Illán-Gala, Ignacio, et al.
Publicado: (2018)

Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome
por: Belbin, Olivia, et al.
Publicado: (2020)

Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis
por: Dols-Icardo, Oriol, et al.
Publicado: (2020)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2021)

Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2023)

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease
por: Leitão, Maria João, et al.
Publicado: (2019)

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer’s disease
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2019)

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
por: Fortea, Juan, et al.
Publicado: (2020)

Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly
por: Pegueroles, Jordi, et al.
Publicado: (2020)

YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies
por: Querol-Vilaseca, Marta, et al.
Publicado: (2017)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome
por: Bejanin, Alexandre, et al.
Publicado: (2021)

Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome
por: Videla, Laura, et al.
Publicado: (2022)

Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans: CSF AD biomarkers measured by Lumipulse in Koreans
por: Moon, Sohee, et al.
Publicado: (2021)

Nanoscale structure of amyloid-β plaques in Alzheimer’s disease
por: Querol-Vilaseca, Marta, et al.
Publicado: (2019)

VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome
por: Iulita, M Florencia, et al.
Publicado: (2023)

Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease
por: Benejam, Bessy, et al.
Publicado: (2022)

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders
por: Alcolea, Daniel, et al.
Publicado: (2019)

Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease
por: Vilaplana, Eduard, et al.
Publicado: (2020)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2020)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2021)

Analytical evaluation of the novel Lumipulse G BRAHMS procalcitonin immunoassay
por: Ruzzenente, Orazio, et al.
Publicado: (2016)

Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®) system
por: Nojima, Hisashi, et al.
Publicado: (2022)

Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies
por: Reyes-Leiva, David, et al.
Publicado: (2022)

Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests
por: Benejam, Bessy, et al.
Publicado: (2020)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
por: Pentz, Rowan, et al.
Publicado: (2020)

Cortical microstructure in primary progressive aphasia: a multicenter study
por: Illán-Gala, Ignacio, et al.
Publicado: (2022)

Correction: Cortical microstructure in primary progressive aphasia: a multicenter study
por: Illán-Gala, Ignacio, et al.
Publicado: (2023)

The validation of macroprolactin analysis by polyethylene glycol precipitation using Fujirebio Lumipulse
por: Vermue, Febe C., et al.
Publicado: (2022)

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
por: Wilson, Edward N., et al.
Publicado: (2022)

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum
por: Goossens, Julie, et al.
Publicado: (2023)

Comparison of “Lumipulse anti‐Treponema pallidum” and “Architect Syphilis TP” and further examination
por: Liang, Jianbo, et al.
Publicado: (2020)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
por: Marksteiner, Josef, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9crhdphioj34l2s2766opdkcg2